---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-015725"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:31:28.180701+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma Series L Preferred holders waive redemption rights – all holders now in agreement

## Summary
- All Series L 10% Convertible Preferred Stock holders have waived redemption rights under Section 10 of the Certificate of Designations.
- Additional holder provided waiver on September 25, 2025, completing the agreement across all holders.
- Waiver eliminates potential redemption trigger that could require cash outlay, improving liquidity.
- No financial impact disclosed; modification alters preferred stockholder rights.

## SEC filing metadata
- accession: 0001493152-25-015725
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315225015725/0001493152-25-015725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315225015725/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-015725
- JSON: https://secwatch.observer/filing/0001493152-25-015725.json
- Plain text: https://secwatch.observer/filing/0001493152-25-015725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.